An interventional study of Spectra Optia CMNC and COBE Spectra MNC in Healthy Apheresis Donors and Mononuclear (MNC) Cell Donors, sponsored by Terumo BCT. Completed at 2 sites in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-09-24.
Sponsored by Terumo BCT (part of Terumo Corporation) · Not applicable and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this prospective, randomized, cross-over, multi-center study is to evaluate the performance of the Spectra Optia Apheresis System's CMNC Collection Procedure, compared to the COBE Spectra Apheresis System's MNC Procedure in mobilized healthy donors. Subject safety will be evaluated beginning with mobilization, throughout the collection procedure and for the day following the last collection.
This is a prospective, randomized, cross-over, multi-center study to evaluate the performance of the Spectra Optia system's CMNC Collection Procedure, compared to the COBE Spectra system's MNC Procedure in mobilized healthy donors.
Up to 60 subject may be consented to meet the the enrollment target of 20 complete subjects. Eligible subjects will be randomized to receive either the Spectra Optia CMNC or the COBE Spectra MNC collection procedure first, followed by the opposite on the following day.
Study participation will be up to 14 days: a 7-day screening period, four days for mobilization, one day for the first MNC collection with additional dose of mobilization, one day for the second MNC collection, and safety follow-up the following day.
Subject safety will be evaluated beginning with mobilization, throughout the collection procedure and for the day following the second collection.
Terumo BCT is the lead sponsor of 14 studies on the registry; none are open to participants now.
First submitted after Terumo BCT became part of Terumo Corporation.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy blood donor criteria as defined by the American Associate of Blood Banks (AABB)
a) Note: Subjects who are deferred from volunteer donations because of travel restrictions, piercings or tattoos may participate in the study
Acceptable prescreening laboratory results prior to MNC mobilization as specified below:
a) WBC 3,500 - 10,800/µL
b) Hematocrit 38% - 56%
c) 150,000 - 400,000/µL
d) Coagulation tests:
i. PT 9.0 - 13.0 seconds
ii. 23.4 - 41.8 seconds
e) Serum electrolytes:
i. Potassium 3.6 - 5.1 mmol/L
ii. Serum Calcium 8.5 mg/dL - 10.3 mg/dL
f) Renal function: Serum creatinine ≤ 1.5 mg/dL
NOTE: up to two laboratory results may fall out of the ranges listed above if, in the judgment of the investigator, they do not constitute a significant risk to the subject.
Willing to avoid pregnancy until at least 48 hours following last G-CSF injection
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Spectra Optia CMNC collection procedure followed by COBE Spectra MNC collection procedure.
Device: Spectra Optia CMNC · Device: COBE Spectra MNC · Drug: Granulocyte-colony stimulating factor (G-CSF)
COBE Spectra MNC collection procedure followed by Spectra Optia CMNC collection procedure.
Device: Spectra Optia CMNC · Device: COBE Spectra MNC · Drug: Granulocyte-colony stimulating factor (G-CSF)
The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself (centrifuge, centrifuge filler, pumps, valves, computerized safety and control systems, etc.), 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software. The Spectra Optia system's investigational CMNC procedure will be used to collect MNC from the peripheral blood.
Also known as: Spectra Optia Apheresis System CMNC collection procedure
It is also a centrifugal system that separates whole blood into its cellular and plasma components. The COBE Spectra MNC collection procedure is chosen as the comparator device because it is the reference after which design of the Spectra Optia CMNC collection procedure was modeled.
Also known as: COBE Spectra Apheresis System MNC collection procedure
Each subject received an injection of the G-CSF approximately equivalent to 10 ug/kg body weight subcutaneous per day for 5 days prior to the MNC collection procedure.
Also known as: Mobilization Procedure
CD34+ Collection Efficiency (CE1 %)
The primary endpoint is the CD34+ cell collection efficiency (CE) associated with the Mononuclear Cell (CMNC) Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems. CE is a measurement of device performance calculated using donor and blood product blood counts collected immediately before and after the CMNC collection procedure. The collection efficiency for a given cell type is defined as the percent of processed cells of that cell type that are in fact collected.
Time frame: within 5 minutes upon completion of procedure
CD34+ Collection Efficiency (CE2 %)
Comparison of collection efficiencies associated with the CMNC Cell Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems. CE is a measurement of device performance calculated using donor blood counts immediately before and blood product blood counts immediately after the collection procedure. The collection efficiency for a given cell type is defined as the percent of processed cells of that cell type that are in fact collected.
Time frame: within 5 minutes upon completion of procedure
MNC Collection Efficiency (CE1%)
Comparison of collection efficiencies associated with the CMNC Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems for MNCs. CE1 is a measurement of device performance calculated using donor and blood product blood counts collected immediately before and after the collection procedure. The collection efficiency for a given cell type is defined as the percent of processed cells of that cell type that are in fact collected.
Time frame: within 5 minutes upon completion of procedure
CD34+ Per kg of Body Weight
Time frame: within 5 minutes upon completion of procedure
MNC Product Contamination/Purity (%) - Hematocrit (%)
Time frame: within 5 minutes upon completion of procedure
MNC Product Contamination/Purity (%) - Granulocyte Concentration (10^3/mL)
Time frame: within 5 minutes upon completion of procedure
MNC Product Contamination/Purity (%) - Platelet Concentration (10^3/µL)
Time frame: within 5 minutes upon completion of procedure
MNC Product Contamination/Purity (%) - Platelet Collection Efficiency (CE1 %)
Comparison of collection efficiencies associated with the CMNC Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems for platelets. CE1 is a measurement of device performance calculated using donor and blood product blood counts collected immediately before and after the collection procedure. The collection efficiency for a given cell type is defined as the percent of processed cells of that cell type that are in fact collected.
Time frame: within 5 minutes upon completion of procedure
MNC Blood Product Volume (mL)
The produced unit of MNCs collected into the blood bag.
Time frame: within 5 minutes upon completion of procedure
Purity of Plasma Collected for Laboratory Processing of MNC Product - Platelet Concentration in Plasma (10^3/µL)
A small amount of plasma typically used for processing was collected in a sub-set of collection procedures.
Time frame: within 5 minutes upon completion of procedure
Procedure Time (Minutes)
Time frame: within 5 minutes upon completion of procedure
MNC Collection Efficiency (CE2%)
Comparison of collection efficiencies associated with the CMNC Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems for MNCs. CE2 is a measurement of device performance calculated using donor blood counts immediately before and blood product counts immediately after the collection procedure and does not average the donor pre- and post-collection counts. The collection efficiency for a given cell type is defined as the percent of processed cells of that cell type that are in fact collected.
Time frame: within 5 minutes upon completion of procedure
MNC Product Contamination/Purity - RBC Concentration (10^6/µL)
Time frame: within 5 minutes upon completion of procedure
Device Deficiencies
Any time a device or disposable does not function as described in the Operator's Manual or Package Insert, a Device Deficiency must be reported. This includes those instances wherein Operator Error led to a malfunction/deficiency. A device deficiency is any inadequacy in the identity, quality, durability, reliability, safety or performance of an investigational device, including malfunction, use errors or inadequacy in the information supplied by the manufacturer. Device malfunctions and device incidents should be reported in the same manner.
Time frame: 24-hours after last collection procedure
Post-collection Platelet Loss in Subject
The percent change from pre-collection platelet count to post-collection subject platelet count.
Time frame: 24-hours after last collection procedure
Subjects were recruited from the specialized donor population of blood centers from August 2014 through January 2015.
| Milestone | Lead-in Donor | Spectra Optia CMNC First, Then COBE Spectra MNC | COBE Spectra MNC First, Then Spectra Optia CMNC |
|---|---|---|---|
| Started | 1 | 12 | 10 |
| Completed | 1 | 12 | 10 |
| Not completed | 0 | 0 | 0 |
The primary endpoint is the CD34+ cell collection efficiency (CE) associated with the Mononuclear Cell (CMNC) Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems. CE is a measurement of device performance calculated using donor and blood product blood counts collected immediately before and after the CMNC collection procedure. The collection efficiency for a given cell type is defined as the percent of processed cells of that cell type that are in fact collected.
| percent | Treatment Assignment 1 | Treatment Assignment 2 |
|---|---|---|
| Spectra Optia | 87.7 ± 20.18 | 81.4 ± 10.24 |
| COBE Spectra | 66.6 ± 20.26 | 65.8 ± 6.40 |
Comparison of collection efficiencies associated with the CMNC Cell Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems. CE is a measurement of device performance calculated using donor blood counts immediately before and blood product blood counts immediately after the collection procedure. The collection efficiency for a given cell type is defined as the percent of processed cells of that cell type that are in fact collected.
| percent | Treatment Assignment 1 | Treatment Assignment 2 |
|---|---|---|
| Spectra Optia | 64.7 ± 14.61 | 59.6 ± 6.17 |
| COBE Spectra | 47.0 ± 14.86 | 50.2 ± 4.20 |
Comparison of collection efficiencies associated with the CMNC Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems for MNCs. CE1 is a measurement of device performance calculated using donor and blood product blood counts collected immediately before and after the collection procedure. The collection efficiency for a given cell type is defined as the percent of processed cells of that cell type that are in fact collected.
| percent | Treatment Assignment 1 | Treatment Assignment 2 |
|---|---|---|
| Spectra Optia CE1 | 62.06 ± 17.220 | 63.75 ± 18.900 |
| COBE Spectra CE1 | 45.46 ± 6.483 | 48.58 ± 14.685 |
| cells/kg | Treatment Assignment 1 | Treatment Assignment 2 |
|---|---|---|
| Spectra Optia | 5.14 ± 3.756 | 3.75 ± 1.506 |
| COBE Spectra | 3.50 ± 2.732 | 3.68 ± 1.546 |
| % of red blood cells | Treatment Assignment 1 | Treatment Assignment 2 |
|---|---|---|
| Spectra Optia Hematocrit | 6.1 ± 2.12 | 3.7 ± 0.95 |
| COBE Spectra Hematocrit | 4.5 ± 1.54 | 5.7 ± 1.71 |
| cells*10^3/mL | Treatment Assignment 1 | Treatment Assignment 2 |
|---|---|---|
| Spectra Optia | 51.689 ± 35.5970 | 63.338 ± 44.9682 |
| COBE Spectra | 83.792 ± 58.9491 | 70.944 ± 72.4223 |
| cells*10^3/µL | Treatment Assignment 1 | Treatment Assignment 2 |
|---|---|---|
| Spectra Optia | 3724.9 ± 962.42 | 2022.9 ± 674.91 |
| COBE Spectra | 2857.4 ± 467.44 | 3736.0 ± 1200.88 |
Comparison of collection efficiencies associated with the CMNC Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems for platelets. CE1 is a measurement of device performance calculated using donor and blood product blood counts collected immediately before and after the collection procedure. The collection efficiency for a given cell type is defined as the percent of processed cells of that cell type that are in fact collected.
| percent | Treatment Assignment 1 | Treatment Assignment 2 |
|---|---|---|
| Spectra Optia | 28.7 ± 14.08 | 23.5 ± 8.62 |
| COBE Spectra | 27.9 ± 9.19 | 30.3 ± 9.85 |
The produced unit of MNCs collected into the blood bag.
| mL | Treatment Assignment 1 | Treatment Assignment 2 |
|---|---|---|
| Spectra Optia | 144.8 ± 32.99 | 141.3 ± 30.82 |
| COBE Spectra | 140.8 ± 28.36 | 137.7 ± 28.64 |
A small amount of plasma typically used for processing was collected in a sub-set of collection procedures.
| cells*10^3/µL | Treatment Assignment 1 | Treatment Assignment 2 |
|---|---|---|
| Spectra Optia | 32.5 ± 30.41 | 8.7 ± 5.86 |
| COBE Spectra | 147.5 ± 4.95 | 179.3 ± 72.47 |
| minutes | Treatment Assignment 1 | Treatment Assignment 2 |
|---|---|---|
| Spectra Optia | 153.8 ± 30.90 | 151.4 ± 27.55 |
| COBE Spectra | 151.1 ± 31.92 | 146.7 ± 27.35 |
Any time a device or disposable does not function as described in the Operator's Manual or Package Insert, a Device Deficiency must be reported. This includes those instances wherein Operator Error led to a malfunction/deficiency. A device deficiency is any inadequacy in the identity, quality, durability, reliability, safety or performance of an investigational device, including malfunction, use errors or inadequacy in the information supplied by the manufacturer. Device malfunctions and device incidents should be reported in the same manner.
| events | Spectra Optia | COBE Spectra |
|---|---|---|
| Device Deficiencies | 1 | 0 |
The percent change from pre-collection platelet count to post-collection subject platelet count.
| percent change | Treatment Assignment 1 | Treatment Assignment 2 |
|---|---|---|
| Spectra Optia | 27.2 ± 9.88 | 23.9 ± 8.04 |
| COBE Spectra | 27.2 ± 9.42 | 30.7 ± 6.18 |
Comparison of collection efficiencies associated with the CMNC Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems for MNCs. CE2 is a measurement of device performance calculated using donor blood counts immediately before and blood product counts immediately after the collection procedure and does not average the donor pre- and post-collection counts. The collection efficiency for a given cell type is defined as the percent of processed cells of that cell type that are in fact collected.
| percent | Treatment Assignment 1 | Treatment Assignment 2 |
|---|---|---|
| Spectra Optia CE2 | 50.99 ± 16.590 | 52.98 ± 17.528 |
| COBE Spectra CE2 | 37.77 ± 5.297 | 39.72 ± 13.972 |
| RBC*10^6/µL | Treatment Assignment 1 | Treatment Assignment 2 |
|---|---|---|
| Spectra Optia RBC Concentration | 1.029 ± 0.4740 | 0.526 ± 0.1990 |
| COBE Spectra RBC Concentration | 0.653 ± 0.2786 | 0.857 ± 0.2501 |
Collected over AEs were captured per protocol from the first dose of G-CSF until final follow up, which was typically 1 day after the last CMNC Collection Procedure for a total of 7 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pre-collection | — | 0/23 (0%) | 22/23 (95.7%) |
| Spectra Optia | — | 0/23 (0%) | 13/23 (56.5%) |
| COBE Spectra | — | 0/22 (0%) | 16/22 (72.7%) |
| Follow up | — | 0/23 (0%) | 2/23 (8.7%) |
| Event | Pre-collection | Spectra Optia | COBE Spectra | Follow up |
|---|---|---|---|---|
| back painMusculoskeletal and connective tissue disorders | 10/23 | 1/23 | 0/22 | 0/23 |
| bone painMusculoskeletal and connective tissue disorders | 9/23 | 0/23 | 0/22 | 0/23 |
| thrombocytopeniaBlood and lymphatic system disorders | 0/23 | 5/23 | 5/22 | 1/23 |
| platelet count decreasedInvestigations | 0/23 | 0/23 | 5/22 | 0/23 |
| fatigueGeneral disorders | 5/23 | 1/23 | 0/22 | 1/23 |
| hemoglobin decreasedInvestigations | 2/23 | 3/23 | 2/22 | 0/23 |
| paraesthesiaNervous system disorders | 1/23 | 1/23 | 2/22 | 0/23 |
| peripheral sensory neuropathyNervous system disorders | 0/23 | 0/23 | 1/22 | 2/23 |
| palpitationsCardiac disorders | 0/23 | 0/23 | 1/22 | 0/23 |
| hypoaesthesia oralGastrointestinal disorders | 0/23 | 1/23 | 1/22 | 0/23 |
Healthy adult specialized blood donors
| Age, Continuous(years) | Lead-in Donor | Spectra Optia CMNC First, Then COBE Spectra MNC | COBE Spectra MNC First, Then Spectra Optia CMNC | Total |
|---|---|---|---|---|
| Mean | 32 ± NA | 35.4 ± 7.32 | 34.8 ± 8.44 | 35.0 ± 7.51 |
| Sex: Female, Male(Participants) | Lead-in Donor | Spectra Optia CMNC First, Then COBE Spectra MNC | COBE Spectra MNC First, Then Spectra Optia CMNC | Total |
|---|---|---|---|---|
| Female | 0 | 1 | 2 | 3 |
| Male | 1 | 11 | 8 | 20 |
| Ethnicity (NIH/OMB)(Participants) | Lead-in Donor | Spectra Optia CMNC First, Then COBE Spectra MNC | COBE Spectra MNC First, Then Spectra Optia CMNC | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 12 | 10 | 23 |
| Not Hispanic or Latino | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Lead-in Donor | Spectra Optia CMNC First, Then COBE Spectra MNC | COBE Spectra MNC First, Then Spectra Optia CMNC | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 5 | 6 | 12 |
| White | 0 | 6 | 4 | 10 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Weight(kilograms) | Lead-in Donor | Spectra Optia CMNC First, Then COBE Spectra MNC | COBE Spectra MNC First, Then Spectra Optia CMNC | Total |
|---|---|---|---|---|
| Mean | 110 ± NA | 115.23 ± 28.921 | 97.08 ± 26.654 | 107.11 ± 28.124 |
| Height(inches) | Lead-in Donor | Spectra Optia CMNC First, Then COBE Spectra MNC | COBE Spectra MNC First, Then Spectra Optia CMNC | Total |
|---|---|---|---|---|
| Mean | 60 ± NA | 70.8 ± 2.45 | 69.4 ± 4.06 | 69.7 ± 3.83 |
| BMI(kg/m^2) | Lead-in Donor | Spectra Optia CMNC First, Then COBE Spectra MNC | COBE Spectra MNC First, Then Spectra Optia CMNC | Total |
|---|---|---|---|---|
| Mean | 47.36 ± NA | 35.82 ± 9.413 | 30.88 ± 6.050 | 34.17 ± 8.579 |
The record gives a start of Sep 2014, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2015, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Granulocyte Colony-Stimulating Factor